Description
Key facts
Sample types:Cell Lysate,
Reacts with:Human, Mouse, Rat,
Assay type:Sandwich (quantitative),
Sensitivity:= 25.132 pg/mL,
Range:78.125 - 5000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)
Product details:
Acetyl Coenzyme A carboxylase alpha SimpleStep ELISA® kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Acetyl Coenzyme A carboxylase alpha protein in human serum, plasma, saliva and cell culture supernatant. Quantitate Acetyl Coenzyme A carboxylase alpha with 25.132 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Acetyl Coenzyme A Carboxylase Alpha also known as ACC1 is an important enzyme in fatty acid metabolism. It catalyzes the carboxylation of acetyl CoA to form malonyl CoA a critical step in fatty acid synthesis. ACC1 is a large protein with a mass of approximately 265 kDa and is mainly expressed in lipogenic tissues such as liver and adipose tissue. Additional isoforms have been identified with distinct tissue distribution patterns which allow for the regulation of fatty acid metabolism across different tissues.
Biological function summary
Acetyl Coenzyme A Carboxylase Alpha controls the availability of malonyl CoA serving as an important regulator of de novo lipogenesis. It functions as part of a homodimeric complex which is necessary for its optimal enzymatic activity. This regulation contributes to the balance of energy storage and consumption in cells. ACC1 not only facilitates the synthesis of long-chain fatty acids but also coordinates with other cellular processes that depend on lipid availability.
Pathways
ACC1 plays a central role in the fatty acid biosynthesis and energy metabolism pathways. It acts in concert with fatty acid synthase to promote production of fatty acids. ACC1's activity is modulated by several factors including AMP-activated protein kinase (AMPK) which phosphorylates ACC1 leading to its inhibition when energy levels are low. This positioning within the metabolism pathways makes ACC1 a critical point for controlling lipid biosynthesis in response to nutritional and hormonal signals.
Alterations in the activity of Acetyl Coenzyme A Carboxylase Alpha are implicated in conditions such as obesity and type 2 diabetes. Dysregulation of ACC1 leads to aberrant lipid accumulation in tissues contributing to obesity-related insulin resistance. Furthermore the link between ACC1 and fatty acid metabolism associates it with metabolic syndromes. The potential of ACC1 as a pharmacological target has led to research exploring its inhibition as a therapeutic strategy for these metabolic disorders.
